0% found this document useful (0 votes)
62 views8 pages

Pharmacological Treatment of Post-Traumatic Stress Disorder: Jonathan I. Bisson

Post-traumatic stress disorder (PTSD) causes significant distress and is often associated with markedly reduced functioning. Recent reviews have consistently recommended trauma-focused psychological therapies as a first-line treatment for PTSD. This article reviews the available trials of the pharmacological treatment of PTSD and discusses their implications.

Uploaded by

Tete Tonwe
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
62 views8 pages

Pharmacological Treatment of Post-Traumatic Stress Disorder: Jonathan I. Bisson

Post-traumatic stress disorder (PTSD) causes significant distress and is often associated with markedly reduced functioning. Recent reviews have consistently recommended trauma-focused psychological therapies as a first-line treatment for PTSD. This article reviews the available trials of the pharmacological treatment of PTSD and discusses their implications.

Uploaded by

Tete Tonwe
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 8

Advances in Psychiatric Treatment (2007), vol. 13, 119–126  doi: 10.1192/apt.bp.105.

001909

Pharmacological treatment
of post-traumatic stress disorder
Jonathan I. Bisson

Abstract Post-traumatic stress disorder (PTSD) causes significant distress and is often associated with markedly
reduced functioning. Recent reviews have consistently recommended trauma-focused psychological
therapies as a first-line treatment for PTSD. Pharmacological treatments have also been recommended
but not as consistently. This article reviews the available trials of the pharmacological treatment of PTSD
and discusses their implications.

Post-traumatic stress disorder (PTSD) is now well Interest in the prevention of its development
established as a discrete psychiatric disorder with following a traumatic event provoked attempts to
evidence of a distinct neurobiology. Its features have discover effective early psychological interventions.
been refined since it was first introduced as a diagnosis One of these, psychological debriefing, has now
in DSM–III (American Psychiatric Association, 1980) been shown to lack evidence of efficacy (Rose et al,
and the past decade has seen an exponential rise in 2005) but trauma-focused cognitive–behavioural
the number of publications relating to it. The disorder interventions for symptomatic individuals have
is characterised by re-experiencing (e.g. nightmares been shown to be efficacious (e.g. Bryant et al, 1998;
and flashbacks), avoidance, numbing of general Ehlers et al, 2003; Bisson et al, 2004).
responsiveness, and hyperarousal (e.g. irritability Of more pertinence here is the possibility of a new
and hypervigilance) following a traumatic event. area of controversy in the management of PTSD,
It has been estimated to have a lifetime prevalence that of the effectiveness or otherwise of pharmaco­
of 8% in the USA, is deemed to be chronic if it lasts logical approaches. Clinical practice guidelines
for more than 3 months and runs a course whereby com­missioned by the National Institute for Health
around a half recover within 2 years but about a and Clinical Excellence (NICE) recommend that
third continue to have the diagnosis 6 years later medication should be considered a second-line
(Kessler et al, 1995). treatment for PTSD, behind trauma-focused psy­
Factors associated with the development of chological treatments such as trauma-focused
PTSD include lack of perceived social support after cognitive–behavioural therapy and eye movement
the event, marked initial distress, high-impact desensitisation and reprocessing (National Collabor­
trauma (rape has consistently been associated with ating Centre for Mental Health, 2005). My primary
the highest rates), dissociation at the time, past aim in this article is to critically review the evidence
psychiatric history and female gender (Brewin et for a pharmacological approach to the management
al, 2000; Ozer et al, 2003). Over half of PTSD sufferers of PTSD, to allow readers to understand the evidence
will also have another psychiatric disorder (Kessler on which the NICE guidelines have been based and
et al, 1995). As a diagnosis, PTSD has always been draw their own conclusions regarding the role of
associated with a degree of controversy. Some have medication in PTSD.
criticised the very existence of PTSD, arguing that
it is a Western social construct; others acknowledge
its existence but are concerned by probable over- The neurobiology of PTSD
diagnosis (e.g. Tyrer, 2005).
Aside from the controversy over the diagnosis of Our understanding of the neurobiology of PTSD
PTSD, its management has also been controversial. has been greatly informed by work on memory

Jonathan Bisson is a clinical senior lecturer in psychiatry at Cardiff University (Monmouth House, University Hospital of Wales, Heath
Park, Cardiff CF14 4XW, UK. Email: [email protected]). He leads the local traumatic stress service and is an active researcher in this
field. He was recently co-chair of the Guideline Development Group for the National Institute for Clinical Excellence’s clinical practice
guidelines on post-traumatic stress disorder.

119
Bisson

and fear conditioning. The hippocampus and other Determining the efficacy
areas of the temporal lobe are believed to mediate
conscious memories, for example the exact details
of interventions
of a traumatic event. The amygdala is believed to be
Various levels of evidence can be used to assess the
important in the mediation of unconscious memories,
efficacy of interventions but replicated, multi­­centre,
for example the autonomic aspects of the classic fear
large-scale randomised controlled trials (RCTs)
response. The amygdala receives information about
should be considered the gold standard. This level
external stimuli and is involved in determining their
of evidence is lacking for most pharmacological ap-
significance. This then triggers emotional responses,
proaches to PTSD treatment, with the notable excep-
including ‘fight, flight or freezing’ and alterations in
tions of paroxetine and sertraline. Nevertheless, there
stress hormones and catecholamines.
have been RCTs (albeit not necessarily to the gold
Connections between the amygdala, hippocampus
standard) of several pharmacological approaches
and medial prefrontal cortex have been implicated
and here I consider the results of those for drugs
in determining the final fear response. Hippocampal
lesions have been associated with a stronger fear that are currently available.
response and smaller hippocampal volume has been The efficacy of the drugs is described in terms
associated with PTSD in several studies, probably of reduction in clinician-assessed severity of PTSD
representing a pre-existing vulnerability to its symptoms using the results of the NICE meta-
devel­op­ment rather than a neurotoxic consequence analysis in this area (National Collaborating Centre
(Gilbertson et al, 2002). Neuroimaging studies of for Mental Health, 2005). In studies that did not
people with PTSD have shown decreased activity include a clinician-rated outcome measure the results
in medial prefrontal and anterior cingulate areas to of the Impact of Event Scale, a self-report measure,
be correlated with increased activity in the amyg­ are given. Box 1 outlines the statistical terms used
dala (Bremner et al, 1999; Shin et al, 2004). This has in the presentation of the results.
resulted in the proposal that PTSD represents a
failure of medial prefrontal and/or anterior cingulate
networks to regulate amygdala activity, resulting in
hyperreactivity to threat (Bremner, 1999). Box 1  Presentation of results
One of the most enduring neurophysiological
theories in recent times has been that of enhanced • k = number of trials
negative feedback in the hypothalamic–pituitary– • n = total number of participants included in
adrenal axis. Several studies have found low the analysis
cortisol levels in people with PTSD and an opposite • s.m.d. (standardised mean difference): a sta-
response to the dexamethasone suppression test than tistical means of determining the effect size
that seen with severe depression, i.e. there is over­ of a continuous outcome measure. A value
suppression of cortisol release. However, more recent of 0 represents no difference between the
studies have not consistently supported this finding groups
(Young & Breslau, 2005). The finding of increased
• Effect size: in general it is accepted that effect
plasma catecholamine levels in PTSD sufferers has
sizes of < 0.5 are low, < 0.8 medium and > 0.8
also evoked considerable interest, including the
large (Cohen, 1988)
suggestion that an initial adrenergic (adrenaline
and noradrenaline) surge may be associated with • 95% confidence intervals (95% CIs): these
the laying down of traumatic memories (Pitman, figures represent the range of standardised
1989). mean differences within which we can be
Our improved understanding of the neurobiology 95% confident that the true level of differ-
of PTSD does not appear to have driven most ence falls
studies of the efficacy of pharmaco­logical agents • RR (relative risk): in the prevention studies
in the treatment of the disorder, but it has led to the RR is used instead of the s.m.d. to
the development of hypotheses for the potential describe the efficacy of the drug in pre­
effectiveness of some drugs (for example propranolol venting the develop­ment of PTSD. This
and hydrocortisone as early interventions, see statistic compares the risk of developing
below). It has also resulted in attempts to determine PTSD for the active drug group with that
the impact of drugs on the neurobiological processes for the placebo group. A relative risk of
themselves. Citalopram, for example, has now 1 represents no difference between the
been shown to influence the acquisition of fear groups
conditioning (Burghardt et al, 2004).

120 Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/


Pharmacological treatment of PTSD

Prevention of PTSD
3
Three small RCTs of early pharmacological inter­
ventions to prevent PTSD have been published, all 2
of which are likely to have been underpowered to
detect clinically important differences unless of a 1
very large magnitude. The first was based on the
cortisol findings described above and concerned 0
the administration of intravenous hydrocortisone

Amitriptyline
Mirtazapine

Venlafaxine

Olanzapine
Imipramine
to victims of septic shock on an intensive care unit

Phenelzine
Paroxetine

Fluoxetine
-1

Sertraline
in Switzerland (Schelling et al, 2001). The results
were not statistically significant but those receiving
hydrocortisone tended to be less likely to develop
symptoms of PTSD (k = 1; n = 20; RR = 0.17; 95% CI 
0.03–1.17). This has not been replicated in other Fig. 1  Treatment of chronic PTSD: standardised mean
populations, although a case study of four individuals differences with 95% confidence intervals.
with chronic PTSD suggests that it may be worthy
of further investigation (Aerni et al, 2004).
The second study concerned propranolol, a beta-
blocker. It was based on the hypothesis that an In summary, there is not enough evidence to
adrenergic surge beginning almost immediately after advocate the routine prescription of medication to
a traumatic event is associated with the development prevent PTSD. There is some evidence for intravenous
of traumatic memories. Pitman and colleagues (2002) hydrocortisone in people with septic shock, but
hypothesised that, for propranolol to be successful, clearly it is difficult to generalise these results to
individuals would have to start taking it within 6 h other populations. There is also some evidence that
of the trauma. The logistic implications of running a temazepam may help with acute insomnia following
trial with this constraint are daunting, but all credit traumatic events. There has been no research to date
to the researchers in completing a small study of exploring the potential of more commonly used
individuals who were randomly allocated to receive agents such as antidepressants in the immediate or
40 mg propranolol or a placebo four times a day for early aftermath of a traumatic event.
10 days. There was no significant difference in rates
of PTSD between the two groups at 1 month (k = 1;
n = 41; RR = 1.14; 95% CI 0.55–2.35) or 3 months (k = 1;
Treatment of PTSD
n = 41; RR = 1.28; 95% CI 0.69–2.38), with the trend
Much more research has been conducted regarding
being in favour of the placebo group. However,
the efficacy of drugs in the treatment of established
the propranolol group became less physiologically
chronic PTSD (Fig. 1). Perhaps not surprisingly
aroused when they listened to an account of the
the selective serotonin reuptake inhibitors (SSRIs)
traumatic event, which indicates the possibility of
have been investigated more than any other family
some effect but not enough to recommend routine
of drugs, indeed more than any other intervention
prescribing.
in the field. The number of individuals entered
Finally, there has been one small RCT of temazepam
into RCTs of SSRIs outnumbers those included in
given shortly after a traumatic event (Mellman et al,
trauma-focused cognitive–behavioural therapy trials
2002). This is of interest because it has been argued
by over 2:1. There are probably several reasons for
that benzodiazepines may hinder the processing of
this, including the willingness of the pharmaceutical
trauma, but on closer scrutiny such assertions appear
industry to fund studies of drugs with the potential
to be based more on anecdote and, possibly, an anti-
to gain another indication for prescribing. It is a sad
prescribing stance than evidence. From a mean of 14
fact that drugs that have shown some potential but
days after the trauma, individuals in the treatment
have lost their patent are not investigated to the same
arm received 30 mg temazepam daily for 5 days,
degree.
then 15 mg daily for 2 days. There was no statistical
difference in rates of PTSD at the 6-week follow-up
point, although a trend was found in favour of the Selective serotonin reuptake inhibitors
placebo group (k = 1; n = 22; RR = 3.2; 95% CI 0.54– Paroxetine
18.98). The temazepam group had slept significantly
better on the first night, but there was no significant There have been three main well-designed double-
difference between groups at follow-up. blind RCTs of paroxetine. Two of these have been

Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/ 121


Bisson

published (Marshall et al, 2001; Tucker et al, 2001), symptoms as a primary outcome measure. The
the other (SKB 627) has not but the results are within results are less convincing than those for paroxetine
the public domain (National Collaborating Centre and do not reach statistical significance (k = 1; n = 301;
for Mental Health, 2005: p. 69). Paroxetine shows a s.m.d. = −0.28; 95% CI 0.54 to −1.2), but this may be
statistically significant positive effect over placebo explained by insufficient numbers to show a real
(k = 3; n = 1070; s.m.d. = −0.42; 95% CI −0.55 to −0.3). but modest effect.
The tight CIs suggest that this is likely to be an ac-
curate estimate of its efficacy, but the critical question
is how clinically significant this effect is: enough for Tricyclics and monoamine oxidase
it to be granted a licence for PTSD by the UK authori- inhibitors
ties but not enough for it to be recommended in the
NICE guidelines (National Collaborating Centre for The RCTs of tricyclic antidepressants and monoam-
Mental Health, 2005) as a first-line treatment! The ine oxidase inhibitors (MAOIs) are older than those
Guideline Development Group set a priori limits on of SSRIs and their quality is inferior. It is disap-
what they would consider clinically meaningful, and pointing that more trials have not been carried out,
as a result gave only a limited recommendation to particularly given the encouraging results of those
paroxetine as a second-line treatment. This, along that have been published. None of the trials used a
with the widely publicised other potential problems clinician-rated outcome measure and therefore the
associated with paroxetine (Duff, 2004), should result results of the Impact of Event Scale, a self-report
in its cautious use for PTSD. measure, are given.

Sertraline Amitriptyline

One of the most interesting things about sertraline The one study (Davidson et al, 1990) that considered
is that, although it is widely recommended as an the efficacy of amitriptyline was positive but with
effective treatment for PTSD (e.g. Friedman et al, very large confidence intervals, meaning that its true
2000; Stein et al, 2004), PTSD is an indication for effect could be anything between low and very large
its use in the UK in females but not in males. This (k = 1; n = 33; s.m.d. = −0.9; 95% CI −1.62 to −0.18).
suggests that the data presented to the authorities
were not totally convincing. In fact, the NICE figures Imipramine
from four published (Brady et al, 2000; Davidson et al,
The evidence for imipramine (Kosten et al, 1991) is
2001a, 2006; Zohar et al, 2002) and two unpublished
weaker than that for amitriptyline and the effect does
studies (Pfizer 588; Pfizer 589) just fail to achieve
not achieve statistical significance, although the wide
sta­tis­tical significance, with a trend in favour of
confidence intervals mean that its true effect could
sertraline (k = 6; n = 1123; s.m.d. = −0.26; 95% CI −0.51
be a positive one (k = 1; n = 41; s.m.d. = −0.24; 95% CI
to 0.00). Interestingly, the Guideline Development
−0.86 to 0.38).
Group was aware of the two unpublished studies
of sertraline held by Pfizer (Pfizer 588; Pfizer 589).
Despite several requests the full results were not Phenelzine
forth­coming, although enough information was Phenelzine is the only available MAOI with an
obtained to include the studies in the final meta- evidence base for the treatment of PTSD (Kosten et
analysis (National Collaborating Centre for Mental al, 1991) and, like amitriptyline, although the true
Health, 2005: p. 71). The inclusion of these two magnitude of its effect is not known it appears to be
studies reduced the apparent efficacy of sertraline. efficacious (k = 1; n = 37; s.m.d. = −1.08; 95% CI −1.75
Such experiences encourage close scrutiny of to −0.36).
efficacy claims and beg the question ‘How many
other unpublished trials are there?’. Calls for the
pre-registration of RCTs and an undertaking to Other drugs
place all results in the public domain seem to be Mirtazapine
well founded.
There has been one small RCT (Davidson et al, 2003) of
Fluoxetine mirtazapine which was strongly in favour of the drug
(k = 1; n = 21; s.m.d. = −1.89; 95% CI −3.00 to −0.78). It
Fewer individuals have participated in fluoxetine is important to be cautious when interpreting the true
trials than in trials for the other two SSRIs, and effect of any intervention on the basis of one small
only one trial (Martenyi et al, 2002) used a standard­ RCT, but these results suggest that mirtazapine is
ised clinician assessment of the severity of PTSD worthy of further investigation.

122 Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/


Pharmacological treatment of PTSD

Venlafaxine present trauma-focused psychological treatments


are not readily available in the National Health
The results of the single relatively large RCT of Service and there are often long waits for them. This
venlafaxine (Davidson et al, 2006) were disappointing is likely to mean that delay in access to such treatment
and did not achieve statistical significance. They will commonly result in the prescribing of medication
suggest that any positive effects are likely to be at for PTSD as a first-line intervention.
best modest overall (k = 1; n = 358; s.m.d. = −0.14; 95% The NICE guidelines recommend paroxetine and
CI −0.35 to 0.06). mirtazapine as the drugs with most evidence for
widespread use, with amitriptyline and phenelzine
Olanzapine being reserved for initiation by secondary care
The one small RCT of olanzapine (Butterfield et professionals. There are limitations to all these drugs
al, 2001) as a first-line treatment for PTSD was not both in terms of limited evidence (see above) and
positive (k = 1; n = 11; s.m.d. = 0.04; 95% CI −1.19 to their side-effect profiles. It seems likely that many
1.26). However, an underpowered RCT of olanzapine prescribers will continue to feel more comfortable
in the augmentation of SSRIs (Stein et al, 2002) prescribing antidepressants they are more familiar
showed a trend in favour of olanzapine (k = 1; n = 19; with, despite the absence of an evidence base.
s.m.d. = −0.92; 95% CI −1.88 to 0.04), suggesting that
further work in this area is warranted.
What dose?
Risperidone If medication is prescribed it is difficult to determine
Risperidone for PTSD has been investigated only as the best dose from the RCTs because it is well recog­
an adjunct to other medications (Hamner et al, 2003) nised that RCTs that allow increases in dose tend
and it did not appear to be efficacious (k = 1; n = 37; to report high mean doses. More informative is the
s.m.d. = 0.1; 95% CI −0.55 to 0.74). fixed-dose RCT of paroxetine (Marshall et al, 2001),
which showed that 20 mg had much the same effect
as 40 mg. In practice it seems sensible to increase the
Non-RCT trials dose to the minimum known to be possibly effective
and then to monitor for a month before considering
No other true RCTs were identified by the Guide­ further increase, although some studies have shown
line Development Group, although several other increasing benefits beyond a month without an in­
drugs have been used for PTSD. For example, some crease in dose. As with all drugs, the actual dose will
benzodiazepines, including clonazepam, alprazolam, also be influenced by side-effects.
carbamazepine, clonidine and prazosin, have been
reported as being efficacious in open-label trials, case
reports or case series. Further evaluation of these How long should treatment
and other drugs will be required before it can be continue?
determined whether they are effective. However,
the adage ‘absence of evidence is not evidence of If effective, the NICE guidelines recommend that
absence of effect’ holds true. treatment is continued for at least a year (National
Collaborating Centre for Mental Health, 2005). There
is no good evidence for this recommendation, which
Prescribing for PTSD was largely based on clinical experience, although
one trial of sertraline showed a lower relapse rate
The disappointing evidence base for the efficacy 
in those continuing on the active medication for 28
of drugs in PTSD should lead to reduced and 
weeks after a positive response than those on placebo
more cautious prescribing for this condition. The
(Davidson et al, 2001b).
true role of drugs in the management of PTSD
remains unclear. The NICE guidance (National
Collaborating Centre for Mental Health, 2005) is that Adverse effects
drugs should only be used as a second-line treatment,
when trauma-focused psychological treatment has The side-effects associated with the use of these drugs
not worked, is contra­indicated or not wanted by the for other conditions appear to apply to their use in
patient, or to treat a comorbid condition. However, PTSD. The NICE guidelines give no information on
the only way to properly determine the comparative adverse effects by study, although the Guideline
efficacy of drug treatment and trauma-focused Development Group found no significant difference
psychological therapy is through adequate head-to- between paroxetine and placebo on reducing the
head studies, which are yet to be conducted. At likelihood of leaving treatment early (k = 3; n = 1196;

Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/ 123


Bisson

RR = 0.95; 95% CI 0.79–1.15). The same applies for rule it is important to try to reduce substance use first
sertraline (k = 6; n = 1148; RR = 1.10; 95% CI 0.90–1.33), and then reassess before treating the PTSD, although
mirtazapine (k = 1; n = 29; RR = 1.20; 95% CI 0.29–2.82) some centres have reported success with a combined
and venlafaxine (k = 1; n = 358; RR = 0.83; 95% CI treatment approach. With depression and anxiety
0.62–1.12), although fluoxetine was associated with it often depends which appears to be the primary
a greater drop-out rate than placebo (k = 1; n = 131; disorder. If the PTSD predominates then treatment
RR = 0.51; 95% CI 0.28–0.96). of this first is appropriate and often associated with
Some individual studies have reported adverse a concomitant reduction of depressive and anxiety
effects. One RCT (Davidson et al, 2001a) found that, symptoms (National Collaborating Centre for Mental
compared with placebo, sertraline significantly Health, 2005). For some individuals treatment of
increased insomnia, diarrhoea and nausea, and their depression may help them to benefit more from
decreased appetite. An RCT comparing paroxetine psychological treatment for their PTSD.
with placebo (Tucker et al, 2001) found that nausea,
somnolence, dry mouth, asthenia and abnormal
ejaculation had an incidence of at least 10% and The future
twice that of placebo. In one RCT (Davidson et al,
2003) three people taking mirtazapine withdrew There is clearly an urgent need to identify more
because of adverse effects, including sedation, effective pharmacological approaches for the manage­
panic attacks, increased anxiety and irritability. ment of PTSD. Despite the more encouraging picture
Three people taking placebo withdrew because in terms of effectiveness of psychological treatments,
of pain, or lack of efficacy; more people taking not all PTSD sufferers will be able to engage with
mirtazapine had increased appetite and weight these and some would prefer a pharmacological
gain. It is also important to consider the possibility alternative. It is to be hoped that in the future the
of a discontinuation syndrome with the SSRIs, and development of novel agents will be based on an
paroxetine in particular, and to follow the well- improved understanding of the neurobiology of
publicised prescribing details (Duff, 2004). PTSD and translational research, the collaborative
interaction of laboratory and clinical medicine.

What if the patient fails


Declaration of interest
to respond?
J. I. B. was Co-Chair of the Guideline Development
If an individual fails to respond they should be re­ Group and co-author of the NICE guidelines on PTSD
assessed to confirm that PTSD is the correct diagnosis. (National Collaborating Centre for Mental Health,
If it is and trauma-focused psychological treatment 2005). His department has received funding from
has not been offered and is indicated attempts should Wyeth for participation in an RCT of venlafaxine in
be made to arrange this. As regards alternative the treatment of PTSD.
pharmacological approaches, increase in the dose
of a tolerated antidepressant would be appropriate
and, if this is unsuccessful, change to an alternative References
antidepressant. If this does not help, augmentation Aerni, A., Traber, R., Hock, C., et al (2004) Low-dose cortisol for
with olanzapine should be considered. In clinical symptoms of posttraumatic stress disorder. American Journal
practice several individuals will remain symptomatic of Psychiatry, 161, 1488–1490.
American Psychiatric Association (1980) Diagnostic and Statistical
and their distress and/or the risks associated with Manual of Mental Disorders (3rd edn) (DSM–III). APA.
their condition will be considered severe enough Bisson, J. I., Shepherd, J. P., Joy, D., et al (2004) Early cognitive–
to try other pharmacological approaches, although behavioural therapy for post-traumatic stress symptoms after
physical injury. Randomised controlled trial. British Journal of
none can be recommended given the current Psychiatry, 184, 63–69.
evidence base. Brady, K., Pearlstein, T., Asnis, G., et al (2000) Efficacy and safety
of sertraline treatment of posttraumatic stress disorder: a
randomized controlled trial. JAMA, 283, 1837–1844.
Bremner, J. D. (1999) Does stress damage the brain? Biological
Comorbidity Psychiatry, 45, 797–805.
Bremner, J. D., Staib, L. H., Kaloupek, D., et al (1999) Neural
It is vital to determine whether an individual with correlates of exposure to traumatic pictures and sound in Viet­
nam combat veterans with and without posttraumatic stress
PTSD has a comorbid psychiatric disorder. Over disorder: a positron emission tomography study. Biological
half of sufferers will have and often this comorbid Psychiatry, 45, 806–816.
condition will need treating in its own right. The most Brewin, C. R., Andrews, B. & Valentine, J. D. (2000) Meta-analysis
of risk factors for post-traumatic stress disorder in trauma-
common co-diagnoses are depressive disorders, other exposed adults. Journal of Consulting and Clinical Psychology,
anxiety disorders and substance misuse. As a general 68, 748–766.

124 Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/


Pharmacological treatment of PTSD

Bryant, R. A., Harvey, A. G., Dang, S. T., et al (1998) Treatment of Pitman, R. K. (1989) Post-traumatic stress disorder, hormones,
acute stress disorder: a comparison of cognitive–behavioural and memory. Biological Psychiatry, 26, 221–223.
therapy and supportive counselling. Journal of Consulting and Pitman, R. K., Sanders, K. M., Zusman, R. M., et al (2002) Pilot
Clinical Psychology, 66, 862–866. study of secondary prevention of posttraumatic stress disorder
Burghardt, N. S., Sullivan, G. M., McEwen, B. S., et al (2004) The with propranolol. Biological Psychiatry, 51, 189–192.
selective serotonin reuptake inhibitor citalopram increases Rose, S., Bisson, J., Churchill, R., (2002) Psychological debriefing
fear after acute treatment but reduces fear with chronic treat- for preventing post traumatic stress disorder (PTSD). Cochrane
ment: a comparison with tianeptine. Biological Psychiatry, 55, Database of Systematic Reviews, issue 2. Art. No.: CD000560.
1171–1178. DOI: 10.1002/14651858.CD000560.
Butterfield, M. I., Becker, M. E., Connor, K. M., et al (2001) Olanza- Schelling, G., Briegal, J., Roozendaal, B., et al (2001) The effect
pine in the treatment of post-traumatic stress disorder: a pilot of stress doses of hydrocortisone during septic shock on post­
study. International Clinical Psychopharmacology, 16, 197–203. traumatic stress disorder in survivors. Biological Psychiatry,
Cohen, J. (1988) Statistical Power Analysis for the Behavioural 50, 978–985.
Sciences. Lawrence Erlbaum Associates. Shin, L. M., Orr, S. P., Carson, M. A., et al (2004) Regional cerebral
Davidson, J., Kudler, H., Smith, R., et al (1990) Treatment of post­ blood flow in the amygdala and medial prefrontal cortex during
traumatic stress disorder with amitriptyline and placebo. traumatic imagery in male and female Vietnam veterans with
Archives of General Psychiatry, 47, 259–266. PTSD. Archive of General Psychiatry, 61, 168–176.
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., et al Stein, M. B., Kline, N. A. & Matloff, J. L. (2002) Adjunctive
(2001a) Multicenter, double-blind comparison of sertraline olanzapine for SSRI-resistant combat-related PTSD: a double-
and placebo in the treatment of posttraumatic stress disorder. blind, placebo-controlled study. American Journal of Psychiatry,
Archive of General Psychiatry, 58, 485–492. 159, 1777–1779.
Davidson, J., Pearlstein, T., Londborg, P., et al (2001b) Efficacy of Stein, D. J., Zungu-Dirwayi, N., Van der Linden, G. J. H., et al
sertraline in preventing relapse of posttraumatic stress dis- (2004) Pharmacotherapy for post traumatic stress disorder
order: results of a 28 week doubleblind, placebo-controlled (PTSD). Cochrane Library, issue 2. WileyInterscience.
study. American Journal of Psychiatry, 158, 1974–1981. Tucker, P., Zaninelli, R., Yehuda, R., et al (2001) Paroxetine in the
Davidson, J. R. T., Weisler, R. H., Butterfield, C. D. C., et al (2003) treatment of chronic posttraumatic stress disorder: results of
Mirtazapine vs placebo in posttraumatic stress disorder: a pilot a placebo-controlled, flexible dosage trial. Journal of Clinical
trial. Society of Biological Psychiatry, 53, 188–191. Psychiatry, 62, 860–868.
Davidson, J., Baldwin, D., Stein, D. J., et al (2006) Treatment Tyrer, P. (2005) From the Editor’s desk. British Journal of Psychiatry,
of posttraumatic stress disorder with venlafaxine extended 186, 552.
release: a 6-month randomized controlled trial. Archives of Young, E. A. & Breslau, N. (2005) Cortisol and catecholamines in
General Psychiatry, 63, 1158–1165. posttraumatic stress disorder: an epidemiologic community
Duff, G. (2004) Safety of Selective Serotonin Reuptake Inhibitor Anti- study. Archives of General Psychiatry, 61, 394–401.
depressants. Committee on Safety of Medicines. http://www.  Zohar, J., Amital, D., Miodownik, C., et al (2002) Double-blind
info.doh.gov.uk/doh/embroadcast.nsf/vwDiscussionAll/ placebo-controlled pilot study of sertraline in military
9AA9EC56B07B3B4F80256F61004BAA88 veterans with posttraumatic stress disorder. Journal of Clinical
Ehlers, A., Clark, D. M., Hackmann, A., et al (2003) A randomized Psychopharmacology, 22, 190–195.
controlled trial of cognitive therapy, a self-help booklet, and
repeated assessments as early interventions for posttraumatic
stress disorder. Archives of General Psychiatry, 60, 1024–1032.
Friedman, M. J., Davidson, J. R. T. & Mellman, T. A. (2000) MCQs
Pharmaco­therapy. In Effective Treatments for PTSD: Practice
Guidelines from the International Society for Traumatic Stress 1 In the UK, PTSD is an indication for the following
Studies (eds E. B. Foa, T. M. Keane & M. J. Freidman), pp. in men and/or women:
84–105. Guilford Press. a� sertraline
Gilbertson, M. W., Shenton, M. E., Ciszewski, A., et al (2002) b� fluoxetine
Smaller hippocampal volume predicts pathologic vulnerability
to psychological trauma. Nature Neuroscience, 5, 1242–1247.
c� mirtazapine
Hamner, M. B., Faldowski, R. A., Ulmer, H. G., et al (2003) Adjunc- d� imipramine
tive risperidone treatment in post-traumatic stress disorder: a e� amitriptyline.
preliminary controlled trial of effects on comorbid psychotic
symptoms. International Clinical Psychopharmacology, 18, 1–8. 2 The autonomic aspects of the classic fear response
Kessler, R. C., Sonnega, A., Bromet, E., et al (1995) Posttraumatic are believed to be mediated by the:
stress disorder in the National Comorbidity Survey. Archives
of General Psychiatry, 52, 1048–1060. a� frontal cortex
Kosten, T. R., Frank, J. B., Dan, E., et al (1991) Pharmacotherapy for b� cerebellum
posttraumatic stress disorder using phenelzine or imipramine. c� hippocampus
Journal of Nervous and Mental Disease, 179, 366–370. d� amygdala
Marshall, R. D., Beebe, K. L., Oldham, M., et al (2001) Efficacy
e� parietal lobe.
and safety of paroxetine treatment for chronic PTSD: a fixed-
dose, placebo-controlled study. American Journal of Psychiatry,
158, 1982–1988. 3 RCTs have shown the following not to be statistically
Martenyi, F., Brown, E. B., Zhang, H., et al (2002) Fluoxetine significantly superior to placebo for PTSD:
versus placebo in posttraumatic stress disorder. Journal of a� paroxetine
Clinical Psychiatry, 63, 199–205. b� phenelzine
Mellman, T. A., Bustamante, V., David, D., et al (2002) Hypnotic
medication in the aftermath of trauma. Journal of Clinical
c� mirtazapine
Psychiatry, 63, 1183–1184. d� venlafaxine
National Collaborating Centre for Mental Health (2005) Post- e� amitriptyline.
traumatic Stress Disorder: The Management of PTSD in Adults
and Children in Primary and Secondary Care. National Clinical 4 The NICE guidelines for PTSD recommend mirtaza-
Practice Guideline Number 26. Gaskell & British Psychological pine or paroxetine in the following circumstances:
Society.
Ozer, E. J., Best, S. R., Lipsey, T. L., et al (2003) Predictors of post- a� first-line treatment of PTSD
traumatic stress disorder and symptoms in adults: a meta- b� second-line treatment of PTSD
analysis. Psychological Bulletin, 129, 52–73. c� for combined use

Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/ 125


Bisson

d� for females only


e� only to be initiated in secondary care. MCQ answers

5 As a treatment for PTSD there is no RCT evidence 1 2 3 4 5


regarding the efficacy (or not) of: a T a F a F a F a F
a� mirtazapine b F b F b F b T b F
b� venlafaxine c F c F c F c F c T
c� carbamazepine d F d T d T d F d F
d� olanzapine e F e F e F e F e F
e� fluoxetine.

126 Advances in Psychiatric Treatment (2007), vol. 13. http://apt.rcpsych.org/

You might also like